Epic Sciences
10975 N. Torrey Pines Road
La Jolla
California
92037
United States
Website: http://www.epicsciences.com/
Email: info@epicsciences.com
85 articles about Epic Sciences
-
Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel
4/19/2023
Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region.
-
Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC
4/14/2023
Epic Sciences, Inc., a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.
-
Epic Sciences Expands Executive Team and Welcomes New Chief Financial Officer in Preparation for Rapid Growth
11/1/2022
Epic Sciences, Inc. announces the appointment of William J. Kullback as Chief Financial Officer, while previous CFO, Joel S. Smith, will continue in his other executive roles as General Counsel, Chief Compliance Officer, and Executive Vice President of Corporate Development.
-
EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
6/2/2022
Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, has completed a $43 million first close of its Series F financing.
-
EPIC SCIENCES RAISES $42M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
6/1/2022
Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, has completed a $43 million first close of its Series F financing.
-
EPIC SCIENCES' DefineMBC™ TEST DELIVERS COMPREHENSIVE LIQUID BIOPSY RESULTS FOR METASTATIC BREAST CANCER
5/4/2022
Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu.
-
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
2/24/2022
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients.
-
Epic Sciences Unveils DefineMBC™, A Novel Blood-based Test Designed To Improve Care For Metastatic Breast Cancer Patients
12/16/2021
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer test that includes both cell-based and cell-free analysis from a single blood draw.
-
EPIC sciences platform Demonstrates compelling Value of Cell Analysis in data Presented AT San Antonio Breast Cancer Symposium 2021
12/8/2021
Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.
-
Epic Sciences Enters Into Exclusive Licensing Agreement and Collaboration With USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology
11/19/2020
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience.
-
Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners
10/29/2020
Epic’s Comprehensive Cancer Profiling™ now includes the broadest ctDNA assay PredicineATLAS™
-
Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsy
5/26/2020
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020 . Epic Sciences will present new data demo
-
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of AR-V7 at 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium
2/6/2020
Epic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13-15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort
-
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
12/5/2019
Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cance
-
Epic Sciences Appoints New Chief Technology Officer
5/22/2019
Epic Sciences, Inc. announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer to help the company advance its Functional Cell Profiling technology to drive global expansion.
-
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
5/15/2019
Epic Sciences, Inc. announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois.
-
Epic Sciences Launches New Corporate Branding and Website
5/13/2019
Epic Sciences, Inc. announced the launch of a new brand identity, redesigned logo, tagline and website.
-
BioSpace Movers and Shakers: April 26
4/26/2019
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more. -
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
-
Epic Sciences Receives CE Mark for Liquid Biopsy Test Collection Kit
4/23/2019
Enables Expanded Access to the Company's Portfolio of Tests